U.S. markets closed
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • Dow 30

    33,761.05
    +424.38 (+1.27%)
     
  • Nasdaq

    13,047.19
    +267.27 (+2.09%)
     
  • Russell 2000

    2,016.62
    +41.36 (+2.09%)
     
  • Crude Oil

    91.88
    -2.46 (-2.61%)
     
  • Gold

    1,818.90
    +11.70 (+0.65%)
     
  • Silver

    20.83
    +0.49 (+2.39%)
     
  • EUR/USD

    1.0257
    -0.0068 (-0.66%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • USD/JPY

    133.4800
    +0.4810 (+0.36%)
     
  • BTC-USD

    24,491.79
    +366.06 (+1.52%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

Merck's Potential Buyout Of Seagen Expected Within Next Few Weeks: Report

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Merck & Co Inc (NYSE: MRK) is in advanced talks to acquire Seagen Inc (NASDAQ: SGEN), and an agreement on a purchase is expected in the next few weeks, Wall Street Journal reported citing people familiar with the matter.

  • The potential deal could be worth roughly $40 billion or more.

  • Related: Merck/Seagen Potential Deal Talks Pick Up Speed.

  • The report added that the companies are discussing a price for Seagen above $200 a share.

  • There is still no guarantee that the companies will reach an agreement on a takeover deal.

  • The transaction can help offset the lower Merck sales when its flagship product Keytruda loses patent protection.

  • According to Cowen estimates, Keytruda could approach 40% of Merck’s sales in 2027.

  • Also Read: This Analyst Believes Seagen Is Evaluating Strategic Alternatives.

  • Any proposed deal is expected to draw a close look from antitrust officials, with Cowen analysts recently predicting “a high likelihood” of litigation from the Justice Department or the Federal Trade Commission.

  • Price Action: SGEN shares are up 4.35% at $182.75 during the premarket session on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.